Voltonik 8 mg/50 mg Effervescent Tablets
Voltonik is a prescription medicine containing 8 mg thiocolchicoside and 50 mg diclofenac potassium per effervescent tablet. Each pack contains 14 tablets.
Prescription only. This page provides product and approved-document information for the medicine authorised in Türkiye.
Voltonik is authorised in the name of Aymed İlaç Sanayi. Each round, yellowish-white effervescent tablet contains 50 mg diclofenac potassium and 8 mg thiocolchicoside.
The Summary of Product Characteristics describes a pack of 14 effervescent tablets in a plastic tube with a polyethylene cap, supplied in a carton with the patient leaflet. The approved Turkish product documents remain the authoritative source of prescribing and use information.
What is Voltonik?
Voltonik contains two active substances. Diclofenac potassium is a non-steroidal anti-inflammatory drug, while thiocolchicoside is a muscle relaxant. A doctor assesses whether the medicine is appropriate in light of the person's health and other medicines.
- Product name
- Voltonik 8 mg/50 mg Effervescent Tablets
- Product group
- Medicinal product
- Active substances
- Thiocolchicoside 8 mg + diclofenac potassium 50 mg
- Pharmaceutical form
- Effervescent tablet
- Strength
- 8 mg / 50 mg
- Pack
- 14 effervescent tablets in a plastic tube and carton
- ATC code
- M03BX55
- Authorisation number
- 2017/342 (Türkiye)
- First authorisation
- 24 May 2017
- Holder (Turkish SmPC)
- AYMED İLAÇ SAN. ve TİC. LTD.ŞTİ.
- Supply status
- Prescription only
Composition and pharmaceutical information
The following information is drawn from the composition, pharmaceutical form and pharmaceutical particulars sections of the Turkish SmPC.
- Composition
- Each tablet contains 50 mg diclofenac potassium and 8 mg thiocolchicoside.
- Appearance
- Round, yellowish-white effervescent tablet.
- Excipients
- Croscarmellose sodium, sodium starch glycolate, sodium carbonate, sorbitol (E420), anhydrous citric acid, potassium bicarbonate, sucralose, lemon flavour and hydrogenated castor oil.
- Shelf life
- 24 months
- Storage
- Store in a dry place at room temperature below 25°C.
Use information and safety
The indications are described in section 1 of the Turkish patient leaflet; contraindications and warnings are in section 2, and instructions for use are in section 3. These should be considered alongside current safety communications. The decision to use the medicine rests with the doctor.
The approved product documents limit treatment to a maximum of 7 consecutive days. Continuing symptoms require reassessment rather than extending treatment without medical advice.
The medicine must not be used during pregnancy or breastfeeding. Plans to have a child and the need for contraception during and after treatment must be discussed with a doctor by both female and male patients. The document's warnings concerning age, gastrointestinal conditions, cardiovascular and kidney disease, allergies and concomitant medicines must be considered.
Healthcare professionals can consult the professional resource summaries and current safety communication alongside the approved documents.
Product documents
The Summary of Product Characteristics (SmPC) is intended for healthcare professionals, while the Patient Information Leaflet (PIL) is written to inform patients about their medicine. This website asks for the existing healthcare-professional declaration before document access. Both approved documents are in Turkish.
Frequently asked questions
Is Voltonik a prescription medicine?
Yes. Voltonik is a prescription-only medicinal product in Türkiye. A doctor decides whether it is appropriate.
What are the active substances in Voltonik?
Each effervescent tablet contains 8 mg thiocolchicoside and 50 mg diclofenac potassium.
How many tablets are in a pack?
The Turkish SmPC describes a pack of 14 effervescent tablets in a plastic tube inside a carton.
Where are the SmPC and patient leaflet available?
The documents are linked in the Product documents section. The SmPC is intended for healthcare professionals and the patient leaflet for patients. This website requests a healthcare-professional declaration before access. The documents are in Turkish.
Who holds the marketing authorisation?
Section 7 of the Turkish SmPC names AYMED İLAÇ SAN. ve TİC. LTD.ŞTİ. as holder of Turkish marketing authorisation number 2017/342, first granted on 24 May 2017.
This English summary describes the product authorised in Türkiye; it is not a claim of authorisation in another country. Refer to the approved Turkish SmPC and patient leaflet for the authoritative product information. Discuss questions about your medicine with your doctor or pharmacist. Sources reviewed and content updated: 26 October 2026.